Wednesday, March 09, 2022 5:35:37 AM
On Feb. 28, the FDA accepted Bristol Myers Squibb’s application for approval of a new use of blockbuster checkpoint inhibitor Opdivo and said it would make a decision by July 13.
That estimate turned out to be conservative, to say the least. On Friday, just five days after accepting the application, the FDA OK’d it, handing the Big Pharma a landmark approval.
Opdivo can now be used to treat patients with early-stage non-small cell lung cancer prior to receiving surgery to remove their tumor.
~Wong, Y@h00 RLFTF financial conversations
==================================
By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).
https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM